Mast cell survival and mediator secretion in response to hypoxia.
Tissue hypoxia is a consequence of decreased oxygen levels in different inflammatory conditions, many associated with mast cell activation. However, the effect of hypoxia on mast cell functions is not well established. Here, we have investigated the effect of hypoxia per se on human mast cell survival, mediator secretion, and reactivity. Human cord blood derived mast cells were subjected to three different culturing conditions: culture and stimulation in normoxia (21% O(2)); culture and stimulation in hypoxia (1% O(2)); or 24 hour culture in hypoxia followed by stimulation in normoxia. Hypoxia, per se, did not induce mast cell degranulation, but we observed an increased secretion of IL-6, where autocrine produced IL-6 promoted mast cell survival. Hypoxia did not have any effect on A23187 induced degranulation or secretion of cytokines. In contrast, cytokine secretion after LPS or CD30 treatment was attenuated, but not inhibited, in hypoxia compared to normoxia. Our data suggests that mast cell survival, degranulation and cytokine release are sustained under hypoxia. This may be of importance for host defence where mast cells in a hypoxic tissue can react to intruders, but also in chronic inflammations where mast cell reactivity is not inhibited by the inflammatory associated hypoxia.
Gulliksson
Magdalena
M
Clinical Immunology and Allergy Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Carvalho
Ricardo F S
RF
Ullerås
Erik
E
Nilsson
Gunnar
G
D000001:Calcimycin / Q000494:pharmacology; D015550:Cell Degranulation / Q000187:drug effects; D015687:Cell Hypoxia; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D017730:Ki-1 Antigen / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008407:Mast Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*
C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D018836:Inflammation Mediators; D015850:Interleukin-6; D017730:Ki-1 Antigen; D008070:Lipopolysaccharides; D000001:Calcimycin
Allergy. 2006 Dec;61(12):1473-9
17073880
Biochim Biophys Acta. 2007 Sep;1771(9):1156-65
17662651
Annu Rev Immunol. 2005;23:749-86
15771585
BMC Immunol. 2008 Jan 23;9:2
18215266
J Immunol. 2007 Sep 1;179(5):3276-86
17709544
Cancer Cell. 2004 Dec;6(6):597-609
15607964
Br J Haematol. 2001 Sep;114(3):616-23
11552987
Exp Cell Res. 2006 Jan 15;312(2):145-55
16289155
Gen Pharmacol. 1998 Oct;31(4):617-23
9792226
Trends Immunol. 2004 May;25(5):235-41
15099563
Blood. 1995 Nov 15;86(10):3705-14
7579337
APMIS. 2002 May;110(5):355-71
12076253
Trends Immunol. 2007 May;28(5):234-41
17400512
J Immunol. 2008 Aug 1;181(3):1665-72
18641302
J Biol Chem. 2003 Oct 3;278(40):38607-16
12874281
J Immunol. 2005 Nov 15;175(10):6257-63
16272275
Biochem Biophys Res Commun. 2003 Jul 11;306(4):805-11
12821113
Immunology. 2003 Jan;108(1):89-97
12519307
Cardiovasc Res. 1999 Apr;42(1):104-12
10435001
J Appl Physiol (1985). 2003 Jan;94(1):325-34
12391033
J Clin Invest. 2006 Oct;116(10):2748-56
16964309
J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):135-48
12808487
J Immunol. 1996 Jul 1;157(1):343-50
8683136
Clin Exp Allergy. 2004 Nov;34(11):1660-4
15544587
Pharmacol Ther. 2007 Feb;113(2):229-46
17046066
Circ Res. 2006 Sep 29;99(7):675-91
17008597
Clin Exp Immunol. 2007 Apr;148(1):161-7
17286758
J Allergy Clin Immunol. 2006 Jun;117(6):1277-84
16750987
Nat Rev Immunol. 2004 Oct;4(10):787-99
15459670
Arthritis Rheum. 1984 Aug;27(8):841-4
6466392
Br J Surg. 2003 Dec;90(12):1470-8
14648724
J Immunol. 2004 Jan 1;172(1):593-600
14688371